Plonmarlimab
As of the edition of 20 October 2026, Plonmarlimab is an antibody: in active development; acts on CSF2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 6, 0 stopped early
- Disease areas
- Bones, joints and muscles; Blood and lymph; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF2 | Granulocyte-macrophage colony-stimulating factor | P04141 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| I-Mab Biopharma | Lead sponsor of trials | 2019 to now |
| TJ Biopharma | Lead sponsor of trials | 2023 to now |